Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kisspeptin in Hypothalamic Amenorrhea
NCT07224438Phase 2Recruiting
- Start
- Dec 2025
- Primary completion
- May 2030
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of kisspeptin 112-121 in hypothalamic amenorrhea (HA). Primary endpoint: Change of luteinizing hormone (LH) pulse amplitude at 2 weeks. Started Dec 2025; status: recruiting.
02
Drugs
kisspeptin 112-121
03
Conditions
hypothalamic amenorrhea (HA)
Beyond the preview
Go deeper on NCT07224438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07224438.